VivoSeq
Metabolic & Endocrine

Sitosterolemia

3

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Sitosterolemia is an early-stage landscape with 3 programs across 0 companies. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical1

Ezetimibe

Organon and Co

Phase 1
No programs
Phase 2
No programs
Phase 32

MK0653, Ezetimibe

Organon and Co

SCH-58235

National Heart, Lung, and Blood Institute (NHLBI)

Approved
No programs

Analysis

Trial Status

6

clinical trials

Completed6 · 100%

Clinical Trials

Trial Activity

6 trials

An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)
Completed·—·Phase 3·NCT00092898·30 enrolled
Sitosterolemia Extension Study (0653-003)(COMPLETED)
Completed·—·Phase 3·NCT00092807·37 enrolled
Sitosterolemia Metabolism
Completed·UUniversity of Manitoba·N/A·NCT01584206·8 enrolled
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00099996·3 enrolled
SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00045812·5 enrolled
Sitosterolemia Extension Study (0653-004)(COMPLETED)
Completed·—·Phase 3·NCT00092820·58 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)